Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 100 movers: Bunzl gains on upgrade; GSK slumps on acquisition
(Sharecast News) - London's FTSE 100 was down 0.4% at 10,332.58 in afternoon trade on Tuesday. Bunzl was up after Exane BNP Paribas upgraded the shares to 'outperform' from 'neutral' and hiked the price target to 3,000p from 2,450p as it said the market has priced the company for permanent damage, but overshot.
Exane said it met with Bunzl's chief executive last week and the meetings gave it increased confidence that the remedial actions and operational changes implemented in North America are bearing fruit.
"Execution issues in North America appear remedied - confirmed in our meetings with the CEO last week - and this de-risks the earnings base just as plastics-led inflation begins flowing through Bunzl's fast-repricing SME model," the bank said.
"On circa 9% free cash yield and priced for just 1% LT annual profit growth, the shares look too cheap."
GSK was under the cosh after it agreed to buy Boston-based oncology-focused biopharmaceutical firm Nuvalent for $10.6bn (£7.9bn).
Russ Mould, investment director at AJ Bell, said: "The initial share price response indicates some trepidation among investors which is understandable given the size of the takeover. GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by Miels in heralding the takeover still await regulatory approval. Any acquisition of this size will always face challenges around integration."
Software-related stocks were in the red again, with Sage Group, Relx and Experian all lower.
FTSE 100 - Risers
Croda International (CRDA) 2,964.00p 3.63% Metlen Energy & Metals (MTLN) 41.18p 3.23% Bunzl (BNZL) 2,560.00p 2.65% IG Group Holdings (IGG) 1,882.00p 2.40% Entain (ENT) 584.60p 2.18% Burberry Group (BRBY) 1,137.00p 2.07% Admiral Group (ADM) 3,358.00p 1.63% JD Sports Fashion (JD.) 85.20p 1.58% Diageo (DGE) 1,519.50p 1.50% Airtel Africa (AAF) 349.00p 1.45%
FTSE 100 - Fallers
Standard Chartered (STAN) 1,867.50p -3.00% AstraZeneca (AZN) 13,512.00p -2.09% The Sage Group (SGE) 845.20p -1.93% HSBC Holdings (HSBA) 1,343.00p -1.79% Glencore (GLEN) 580.30p -1.72% BT Group (BT.A) 200.20p -1.62% GSK (GSK) 1,885.00p -1.36% Mondi (MNDI) 737.00p -1.15% Relx plc (REL) 2,573.00p -1.04% Experian (EXPN) 2,610.00p -0.99%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
